Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines

被引：9
作者：
Shoor, Stanford [1 ]
机构：
[1] Stanford Univ, 1000 Welch Rd Suite 203, Palo Alto, CA 94304 USA
来源：
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2020年 / 34卷 / 02期
关键词：
Serious infection; Co-stimulatory molecule inhibitors; IL-17 and IL-23 inhibitors; MODIFYING ANTIRHEUMATIC DRUGS; NECROSIS-FACTOR INHIBITORS; SEVERE PLAQUE PSORIASIS; LONG-TERM EFFICACY; RHEUMATOID-ARTHRITIS; PHASE-III; FUSION PROTEIN; MODERATE; SAFETY; BELATACEPT;
D O I：
10.1016/j.idc.2020.02.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Co-stimulatory T-cell inhibitors are used in the treatment of rheumatoid arthritis and to prevent rejection of renal transplants. Inhibitors of the interleukin (IL)-17 cytokine are indicated for psoriasis, psoriatic arthritis and ankylosing spondylitis and anti- IL-23 drugs for psoriasis. Serious infections occur in 4.2% to 25.0% of co-stimulatory inhibitors and 1.0% to 2.0% with IL-17 or IL-23 inhibitors. Underlying disease, steroid dose greater than 7.5 to 10.0 mg, and comorbidities influence risk in individual patients. Opportunistic infections or reactivation of tuberculosis are rare.
引用
收藏
页码：179 / +
页数：12
相关论文
共 81 条
  • [1] Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis
    Attia, Attia
    Abushouk, Abdelrahman Ibrahim
    Ahmed, Hussien
    Gadelkarim, Mohamed
    Elgebaly, Ahmed
    Hassan, Zeinab
    Abdel-Daim, Mohamed M.
    Negida, Ahmed
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (05) : 439 - 451
  • [2] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Randazzo, Bruce
    Wasfi, Yasmine
    Shen, Yaung-Kaung
    Li, Shu
    Kimball, Alexa B.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) : 405 - 417
  • [3] Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study
    Chiu, Hsien-Yi
    Hui, Rosaline Chung-yee
    Huang, Yu-Huei
    Huang, Ruey-Yun
    Chen, Kai-Lung
    Tsai, Ya-Chu
    Lai, Po-Ju
    Wang, Ting-Shun
    Tsai, Tsen-Fang
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 (09) : 829 - 834
  • [4] IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans
    Conti, Heather R.
    Gaffen, Sarah L.
    [J]. JOURNAL OF IMMUNOLOGY, 2015, 195 (03) : 780 - 788
  • [5] Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis
    Curtis, J. R.
    Yang, S.
    Patkar, N. M.
    Chen, L.
    Singh, J. A.
    Cannon, G. W.
    Mikuls, T. R.
    Delzell, E.
    Saag, K. G.
    Safford, M. M.
    Duvall, S.
    Alexander, K.
    Napalkov, P.
    Winthrop, Kevin L.
    Burton, M. J.
    Kamauu, A.
    Baddley, J. W.
    [J]. ARTHRITIS CARE & RESEARCH, 2014, 66 (07) : 990 - 997
  • [6] Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
    Curtis, Jeffrey R.
    Xie, Fenglong
    Yun, Huifeng
    Bernatsky, Sasha
    Winthrop, Kevin L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (10) : 1843 - 1847
  • [7] Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
    Deodhar, A.
    Mease, P. J.
    McInnes, I. B.
    Baraliakos, X.
    Reich, K.
    Blauvelt, A.
    Leonardi, C.
    Porter, B.
    Gupta, A. Das
    Widmer, A.
    Pricop, L.
    Fox, T.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [8] Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study
    Doran, MF
    Crowson, CS
    Pond, GR
    O'Fallon, WM
    Gabriel, SE
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : 2287 - 2293
  • [9] A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)
    Durrbach, A.
    Pestana, J. M.
    Pearson, T.
    Vincenti, F.
    Garcia, V. D.
    Campistol, J.
    del Carmen Rial, M.
    Florman, S.
    Block, A.
    Di Russo, G.
    Xing, J.
    Garg, P.
    Grinyo, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (03) : 547 - 557
  • [10] A Simple Guide to Comparative Vigilance
    Feldman, Allan M.
    Singh, Ram
    [J]. ASIAN JOURNAL OF LAW AND ECONOMICS, 2011, 2 (03)
123456789